SAB Biotherapeutics, Inc. Common Stock (SABS) is a publicly traded Healthcare sector company. As of May 21, 2026, SABS trades at $3.63 with a market cap of $272.21M and a P/E ratio of 16.77. SABS moved +3.66% today. Year to date, SABS is -1.60%; over the trailing twelve months it is +99.71%. Its 52-week range spans $1.00 to $6.60. Analyst consensus is strong buy with an average price target of $12.17. Rallies surfaces SABS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own SABS include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for SAB Biotherapeutics, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $3.63 |
| Market Cap | $272.21M |
| P/E Ratio | 16.77 |
| EPS | $0.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.60 |
| 52-Week Low | $1.00 |
| Volume | 47 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $13.27M |
| Gross Margin | 0.00% |
7 analysts cover SABS: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.17.